Ionis PharmaceuticalsIONS
IONS
About: Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Employees: 927
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
18% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 50
3.02% more ownership
Funds ownership: 98.61% [Q3] → 101.63% (+3.02%) [Q4]
1% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 118
0% more funds holding
Funds holding: 349 [Q3] → 350 (+1) [Q4]
10% less capital invested
Capital invested by funds: $6.22B [Q3] → $5.61B (-$610M) [Q4]
15% less call options, than puts
Call options by funds: $26.1M | Put options by funds: $30.5M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$39
37%
upside
Avg. target
$53
85%
upside
High target
$70
146%
upside
7 analyst ratings
4 positive
57%
3 neutral
43%
0 negative
0%
Needham Joseph Stringer 21% 1-year accuracy 25 / 118 met price target | 111%upside $60 | Buy Reiterated | 15 Apr 2025 |
HC Wainwright & Co. Mitchell Kapoor 30% 1-year accuracy 56 / 186 met price target | 58%upside $45 | Buy Initiated | 7 Apr 2025 |
Redburn Atlantic Joshua Smith 0% 1-year accuracy 0 / 2 met price target | 37%upside $39 | Neutral Initiated | 31 Mar 2025 |
JP Morgan Jessica Fye 56% 1-year accuracy 20 / 36 met price target | 58%upside $45 | Neutral Maintained | 24 Mar 2025 |
Citigroup David Lebowitz 42% 1-year accuracy 8 / 19 met price target | 125%upside $64 | Buy Maintained | 20 Feb 2025 |
Financial journalist opinion
Based on 5 articles about IONS published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains?
Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neutral
Business Wire
2 weeks ago
Ionis to host expert panel discussion on sHTG
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14th at 11:00 a.m. ET focused on the risks, clinical presentation and significant unmet medical needs associated with severe hypertriglyceridemia (sHTG). Key thought leaders in lipidology, cardiology and endocrinology will join Sam Tsimikas, M.D., senior vice president, global cardiovascular development, Ionis, for a live discussion followed by a brief Q&A se.
Neutral
Business Wire
3 weeks ago
Ionis to present at upcoming investor conferences
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 Bank of America 2025 Health Care Conference on Wednesday, May 14, 2025 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025 A live webcast of these presentations can be accessed on the Investors & Media secti.
Positive
Zacks Investment Research
3 weeks ago
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi
In return, Ionis will receive an undisclosed upfront payment from Sobi. It is also eligible to receive milestone payments and a tiered royalty on the drug's future sales.
Neutral
Business Wire
3 weeks ago
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement under which Sobi® receives exclusive rights in countries outside the U.S., Canada and China to commercialize olezarsen as a potential treatment for familial chylomicronemia syndrome (FCS) and severely elevated triglycerides. Ionis will continue to independently commercialize olezarsen in the U.S. Olezarsen was approved by the FDA in December 2024 under the t.
Positive
Zacks Investment Research
1 month ago
Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Neutral
Business Wire
1 month ago
Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “ONO”) announced that it has entered into a license agreement with Ionis Pharmaceuticals, Inc. (Carlsbad, CA,U.S.; CEO, Brett P. Monia, Ph.D.; “Ionis”) for sapablursen, an investigational RNA-targeted medicine for the treatment of polycythemia vera (PV). Sapablursen is currently being evaluated in adult patients with PV in the fully enrolled Phase 2 IMPRSSION study. Sapablu.
Neutral
Business Wire
1 month ago
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
CARLSBAD, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license agreement in which Ono obtains exclusive global rights for the development and commercialization of sapablursen, an investigational RNA-targeted medicine for polycythemia vera (PV), a rare and potentially life-threatening hematologic disease. Sapablursen is currently being evaluated in adults living.
Neutral
Business Wire
1 month ago
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, commonly referred to as hATTR-PN or ATTRv-PN. WAINZUA is the only approved medicine in the EU for the treatment of ATTRv-PN that can be self-administered monthly via an auto-injector.
Neutral
Business Wire
1 month ago
Ionis to present at upcoming investor conferences
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025 TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11, 2025 Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025 U.
Charts implemented using Lightweight Charts™